S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 3/20 - 3/24
Germany, EU reach agreement in combustion engine row
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
ConocoPhillips details gas leak cause, remedies at hearing
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 3/20 - 3/24
Germany, EU reach agreement in combustion engine row
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
ConocoPhillips details gas leak cause, remedies at hearing
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 3/20 - 3/24
Germany, EU reach agreement in combustion engine row
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
ConocoPhillips details gas leak cause, remedies at hearing
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 3/20 - 3/24
Germany, EU reach agreement in combustion engine row
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
ConocoPhillips details gas leak cause, remedies at hearing
NASDAQ:TBPH

Theravance Biopharma - TBPH Stock Forecast, Price & News

$10.52
+0.18 (+1.74%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.11
$10.60
50-Day Range
$9.87
$11.44
52-Week Range
$7.53
$11.83
Volume
483,645 shs
Average Volume
618,719 shs
Market Capitalization
$665.18 million
P/E Ratio
0.91
Dividend Yield
N/A
Price Target
$16.50

Theravance Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.8% Upside
$16.50 Price Target
Short Interest
Bearish
15.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Theravance Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$88,120 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.75) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

400th out of 989 stocks

Pharmaceutical Preparations Industry

182nd out of 480 stocks


TBPH stock logo

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Earnings Preview: Theravance Biopharma
TBPH Theravance Biopharma, Inc.
See More Headlines
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings
11/02/2021
Today
3/25/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+56.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$872.13 million
Net Margins
1,698.54%
Pretax Margin
-180.76%

Debt

Sales & Book Value

Annual Sales
$51.35 million
Book Value
$6.56 per share

Miscellaneous

Free Float
60,191,000
Market Cap
$665.18 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Rick E. Winningham
    Chairman & Chief Executive Officer
  • Andrew Asa Hindman
    Chief Financial Officer & Senior Vice President
  • Vijay Sabesan
    Senior Vice President-Technical Operations
  • Philip D. Worboys
    Senior VP-Research & Translational Science
  • Bradford J. Shafer
    Secretary, Executive VP & General Counsel













TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TBPH shares.
View TBPH analyst ratings
or view top-rated stocks.

What is Theravance Biopharma's stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Theravance Biopharma's shares. Their TBPH share price forecasts range from $14.00 to $19.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for TBPH
or view top-rated stocks among Wall Street analysts.

How have TBPH shares performed in 2023?

Theravance Biopharma's stock was trading at $11.22 at the beginning of the year. Since then, TBPH stock has decreased by 6.2% and is now trading at $10.52.
View the best growth stocks for 2023 here
.

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our TBPH earnings forecast
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.12. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analyst estimates of $13.55 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 93.49% and a net margin of 1,698.54%. During the same period last year, the company earned ($1.16) EPS.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.69%), Two Sigma Investments LP (1.43%), Bank of America Corp DE (1.30%), Millennium Management LLC (1.00%), Norges Bank (0.81%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham.
View institutional ownership trends
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $10.52.

How much money does Theravance Biopharma make?

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $665.18 million and generates $51.35 million in revenue each year. The biopharmaceutical company earns $872.13 million in net income (profit) each year or $11.54 on an earnings per share basis.

How many employees does Theravance Biopharma have?

The company employs 359 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 3/25/2023 by MarketBeat.com Staff